Fukumitsu Masafumi, Ariyasu Ryo, Ishiyama Mitsutomi, Mochizuki Toshiaki, Takeda Koichi, Ono Makiko, Oyakawa Takuya, Ebihara Aya, Nishizawa Aya, Tomomatsu Junichi, Kogawa Takahiro, Kitano Shigehisa, Shiga Taro
Department of Onco-Cardiology/Cardiovascular Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, 135-8550 Japan.
Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Int Cancer Conf J. 2022 Dec 13;12(2):109-114. doi: 10.1007/s13691-022-00588-1. eCollection 2023 Apr.
Myocarditis associated with immune-checkpoint inhibitors (ICIs) is a rare, but critical adverse event. Although endomyocardial biopsy (EMB) is the standard for diagnosis of myocarditis, there is a possibility of false negatives due to sampling errors and local nonavailability of EMB, which may hamper the appropriate diagnosis of myocarditis. Therefore, an alternative criterion based on cardiac magnetic resonance imaging (CMRI) combined with clinical presentation has been proposed, but not emphasized sufficiently. We report a case of myocarditis after ICIs administration, which was diagnosed using CMRI in a 48-year-old male with lung adenocarcinoma. CMRI provides an opportunity to diagnose myocarditis during cancer treatment.
与免疫检查点抑制剂(ICI)相关的心肌炎是一种罕见但严重的不良事件。虽然心内膜心肌活检(EMB)是心肌炎诊断的标准,但由于取样误差和EMB在当地无法获取,存在假阴性的可能性,这可能会妨碍心肌炎的准确诊断。因此,已经提出了一种基于心脏磁共振成像(CMRI)结合临床表现的替代标准,但尚未得到充分强调。我们报告了一例在ICI给药后发生的心肌炎病例,该病例是在一名48岁的肺腺癌男性患者中通过CMRI诊断出来的。CMRI为在癌症治疗期间诊断心肌炎提供了机会。